| Статус: | Recruiting |
| Фаза: | Phase 3 |
| Начало: | 2 августа 2022 г. |
| Окончание: | 1 апреля 2025 г. |
| Описание: | The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with unresectable or metastatic melanoma. |
| смотреть на ClinicalTrials.gov |
| Статус: | Recruiting |
| Фаза: | Phase 3 |
| Начало: | 1 октября 2019 г. |
| Окончание: | 1 декабря 2024 г. |
| Описание: | This is a randomized, multicenter, double-blind, Phase 3 study of efficacy and safety of BCD-100 plus platinum-based chemotherapy with and without bevacizumab versus placebo plus platinum-based chemotherapy with and without bevacizumab |
| смотреть на ClinicalTrials.gov |
| Статус: | Unknown status |
| Фаза: | Phase 3 |
| Начало: | 1 июня 2019 г. |
| Окончание: | 1 декабря 2023 г. |
| Описание: | This is a randomized, multicenter, double-blind placebo-controlled phase 3 study of efficacy and safety of BCD-100 in combination with pemetrexed+cisplatin/carboplatin compared to placebo in combination with pemetrexed+cisplatin/carboplatin in subjects with previously untreated metastatic non-squamous NSCLC. The main hypothesis of the study is that BCD-100 in combination with chemotherapy prolongs OS compared to placebo with chemotherapy. |
| смотреть на ClinicalTrials.gov |